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Abstract: Down syndrome (DS) is often accompanied by gastrointestinal disease, occurring 
mainly in early infancy and frequently requiring therapy. Among motility disorders, the most 
frequent is gastroesophageal reflux disease (GERD), which may often be misdiagnosed because 
of its atypical manifestations. Early diagnosis of esophageal functional disorders is essential 
to prevent respiratory problems, growth retardation in children, weight loss in adults, and to 
establish the correct type of surgery if needed. Furthermore, the involvement of the enteric 
nervous system in the pathophysiology of GERD in DS is not yet completely understood but 
seems supported by much evidence. In fact DS is often associated with motor disorders and 
this evidence must be considered in the choice of therapy: in particular all options available to 
improve motility seem to be effective in these patients. The effectiveness of therapy is strictly 
related to the rate of mental impairment, so that modulating therapy is essential, especially in 
view of the severity of the neurological status.
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Introduction
Down syndrome (DS) is often accompanied by gastrointestinal disease, mainly 
occurring in early infancy and frequently requiring therapy. Gastrointestinal diseases 
and feeding difficulties represent a frequent cause of hospital admission (19%) in DS.1 
The most common in DS are congenital gastrointestinal diseases, requiring surgery, in 
particular esophageal atresia, duodenal obstructions, ano-rectal malformations (ARM), 
and Hirschsprung’s disease (HSCR). Among motility disorders, the most frequent is 
gastroesophageal reflux disease (GERD).2 Nevertheless, few data on its diagnosis and 
management in DS patients have been published.
Gastrointestinal diseases in DS
The association between gastrointestinal disease and DS is well known: as many as 
77% of DS newborns have or will develop gastrointestinal problems.3 These conditions 
can be classified into mechanical or functional disorders and may be primary or 
secondary.
In particular, the literature reports about a 300-fold increased risk for annular 
  pancreas and duodenal atresia and about a 100-fold increased risk for HSCR, esophageal, 
anal, and small bowel atresia.4 The most common congenital structural defects which 
result in a mechanical neonatal intestinal obstruction include tracheo-esophageal fistula, 
duodenal stenosis/atresia, pyloric stenosis, anular pancreas, and ARM.5,6Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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Functional gastrointestinal obstruction, on the other 
hand, is most frequently due to achalasia, GERD, HSCR, and 
  constipation.3 The involvement of the enteric nervous system 
(ENS) in these associations is not yet completely understood 
but it seems evident by the fact that some of the most   common 
gastrointestinal symptoms reported by DS patients are 
functional ones, such as dysphagia,   vomiting, and heartburn 
as well as other esophageal dysmotility symptoms.7
As regards the physiopathological basis of the association 
between DS and gastrointestinal disease, it is generally 
accepted that the pathological changes in the nervous   system 
of patients with DS probably underlie the physiological 
and neurological features of the associated anomalies of 
the gastrointestinal tract. Developmental defects within the 
ENS are also likely to be the cause of significant functional 
disorders. There is some evidence that the decrease in normal 
development of the nervous system in DS may be due either 
to the basis of decreased neuronal migration or to a failure of 
the normal dendritic development within nervous system.8 
In addition, in DS patients there may also be an ongoing 
loss of neural cells in the ENS, similar to that occurring in 
the brain.9
GERD and DS
GERD remains one of the most frequent causes of esopha-
geal symptomatology in DS but runs the risk of being 
underestimated.10 Previous studies report a 43% occurrence 
of serious complications arising from GERD in DS patients. 
In addition, oropharingeal aspiration may be associated 
with pneumonia and aspiration syndromes in dysphagic 
neurological patients, such as DS.11
According to the Montreal Definition and Classification 
of GERD,12 GERD is a condition that develops when the 
reflux of stomach contents causes troublesome symptoms 
and/or complications. The same definition is actually adopted 
in pediatric age, in which some peculiar characteristics are 
evident: symptoms vary by age and are troublesome when 
they have an adverse effect on the well-being of children; 
reflux symptoms that are not troublesome should not be 
diagnosed as GERD; bilious   vomiting should not be diag-
nosed as GERD; pediatric patients with central nervous 
system impairment have an increased risk of GERD; 
typical reflux symptoms are not sufficient to diagnose 
GERD in children who lack the cognitive ability to report 
symptoms; atypical and/or respiratory symptoms may 
be the unique manifestations of GERD in neurologically 
impaired children; esophageal   complications of GERD are 
esophagitis, hemorrhage, stricture, Barrett’s esophagus and, 
rarely, adenocarcinoma.13
GERD is widely known to have a high incidence 
in neurologically impaired children,14 who often show 
atypical symptoms of this condition, however, a high 
index of suspicion is required to discover GERD and its 
complications.15–17
No single investigation can definitely diagnose GERD. 
Therefore the choice is based on the clinical context. 
A 24-hour pH-metry remains the gold standard in   diagnosing 
GERD. Radiography and pulmonary scintiscan may be use-
ful in identifying the presence of aspiration. The barium 
contrast upper gastrointestinal study is also helpful in iden-
tifying the presence of hiatus hernia, strictures, swallowing 
disturbances, the motility of esophagus and stomach and to 
rule out   anatomical anomalies. Gastroscopy is   helpful in 
detecting reflux esophagitis and biopsies are taken to assess 
its severity. Esophageal manometry is useful to detect motor 
esophageal disorders (especially in neurologically impaired 
patients) and the competence of the lower esophageal 
sphincter.18
In addition, DS seems to be associated with primary 
and secondary esophageal motility disorders, for unknown 
causes. Thus, patients with either frequent esophageal symp-
toms and/or atypical manifestations such as food rejection, 
frequent vomiting, coughing, and failure to thrive should 
be evaluated for esophageal function. Early diagnosis of 
esophageal functional disorders is essential to prevent 
respiratory problems, growth retardation in children, weight 
loss in adults, and to establish the correct type of surgery 
if needed.7
Treatment of GERD in DS
The rationale in the treatment of GERD is focused on 
decreasing the symptoms, the frequency and duration of 
reflux events, healing the injured mucosa and preventing 
complications.19
The treatment of GERD in DS is based on the protocols 
of treatment of GERD in the normal pediatric population. 
Two fundamental aspects must be kept in mind. First, DS is 
often associated with motor disorders and this evidence has 
to be considered in the choice of therapy: in particular all the 
options available to improve motility seem to be effective in 
these patients. Second, the effectiveness of therapy is strictly 
related to the rate of mental impairment, so that modulating 
therapy is mandatory especially in view of the severity of 
the neurological status.Clinical and Experimental Gastroenterology 2011:4 submit your manuscript | www.dovepress.com
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GERD therapy consists of a combination of the following 
options:
Conservative treatment
Frequent small feeds of thickened formula or food minimize 
gastric distension and reduce GERD. Elevation of the upper 
body at 60°, maintained for 24 hours a day, aids esophageal 
clearance and effectively reduces symptoms of reflux in 
two-thirds of infants while awake and during sleep.20
Medical treatment
If conservative measures do not improve symptoms, medical 
therapy is recommended. Pharmacological therapies are 
aimed at the various steps in the pathophysiology of GERD. 
These include the use of antacids, hydrogen ion-blocking 
drugs, proton pump inhibitors (PPI) and prokinetics agents.21 
Antacids work by neutralizing gastric acids.   Prokinetics 
work by increasing esophageal peristalsis, increasing 
the lower esophageal sphincter pressure, and enhancing 
  gastric emptying, even if their effectiveness has not yet 
been universally accepted.22 H2-blockers and PPIs work by 
decreasing the secretion of gastric acids.23 The advent of PPI 
in particular has strongly influenced the treatment of GERD, 
especially in neurologically impaired children.24
Surgical treatment
Surgery for GERD is one of the most common major 
operations in children. The primary indication in   performing 
an anti-reflux operation is the control of intractable or 
  life-threatening GERD: surgical treatment is usually 
  performed after unsuccessful trials of prolonged medical 
therapy, in patients with severe complications of reflux, such 
as aspiration, failure to thrive or esophagitis with strictures 
or   Barrett’s esophagus.25 The major objectives of operative 
repair are to increase the high pressure zone in the lower 
esophagus by accentuating the angle of His and increasing 
the length of the abdominal esophagus. The most widely 
used fundoplication procedure was originally described by 
Nissen and Rossetti, and consists of the intra-abdominal 
  positioning of the distal esophagus, hiatus hernia repair, and 
a 360° fundal wrap.26 The technique has been   developed 
and we now have the option of partial fundoplication 
wrapping techniques, which refer to any wrap less than 360°. 
  Laparoscopic   fundoplication can be also   performed safely and 
with   equivalent results in neurologically impaired children.27 
Anti-reflux surgery is characterized by high grade morbidity, 
however, so that a correct indication for surgery is essential. 
Problems with anti-reflux surgery occur especially in children 
with neurological impairment.28 In this context, esophageal 
dysmotility has been shown to   complicate the postoperative 
course following surgical   corrective procedures.29 Alternatives 
to fundoplication, especially in children with neurodevelop-
mental disorders, include insertion of a   gastrojejunal tube 
or jejunostomy.30 These procedures are less invasive but do 
not treat GERD, thus necessitating long-term medical treat-
ment, and require continuous jejunal feeding. An alternative 
operation has recently been proposed for children with severe 
neurological conditions and consists of total esophagogastric 
disconnection.31 The procedure aims to prevent GERD while 
allowing at the same time bolus feeds via the gastrostomy. 
Nevertheless, the technique has a very high complication, 
failure and mortality rate.32 So that it must be limited in very 
few carefully selected patients.14
Conclusion
GERD is frequent in DS, and its severity is strictly related 
to the severity of neurological impairment. Therapy has to 
be chosen according to the underlying causes of GERD and 
to the severity of its complications.
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